

Gano Kyle  
 Form 3  
 January 28, 2013

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Gano Kyle		(Month/Day/Year)	NEUROCRINE BIOSCIENCES INC [NBIX]	
(Last)	(First)	(Middle)	01/16/2013	
NEUROCRINE BIOSCIENCES, INC., Â 12780 EL CAMINO REAL			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)	(Check all applicable)			
	<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)	
	<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other	_X_ Form filed by One Reporting Person	
	(give title below) (specify below)		___ Form filed by More than One Reporting Person	
	Chief Business Dev Officer			
SAN DIEGO, Â CA Â 92130				
(City)	(State)	(Zip)		

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	22,488	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

## Edgar Filing: Gano Kyle - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â <u>(1)</u>	09/26/2013	Common Stock	2,400	\$ 10.9	D	Â
Employee Stock Option (right to buy)	Â <u>(2)</u>	03/12/2015	Common Stock	9,000	\$ 5	D	Â
Employee Stock Option (right to buy)	Â <u>(3)</u>	05/11/2017	Common stock	40,000	\$ 2.59	D	Â
Employee Stock Option (right to buy)	Â <u>(4)</u>	08/25/2021	Common Stock	75,000	\$ 5.76	D	Â
Employee Stock Option (right to buy)	Â <u>(5)</u>	01/12/2022	Common Stock	70,000	\$ 8.66	D	Â
Employee Stock Option (right to buy)	Â <u>(6)</u>	01/10/2023	Common Stock	60,000	\$ 8.65	D	Â
Restricted Stock Unit	Â <u>(7)</u>	Â <u>(7)</u>	Common Stock	10,000	\$ 0 <u>(8)</u>	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gano Kyle NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL SAN DIEGO, CA 92130	Â	Â	Â Chief Business Dev Officer	Â

## Signatures

Margaret E. Valeur- Jensen, By Power of Attorney 01/28/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested in annual installments over three years. The first installment became exercisable on September 26, 2007.
  - (2) The option vested in annual installments over three years. The first installment became exercisable on March 12, 2009.
  - (3) The option vests in monthly installments over three years. The first installment became exercisable on June 11, 2010.
  - (4) The option vests in monthly installments over three years. The first installment became exercisable on September 25, 2011.
  - (5) The option vests in monthly installments over four years. The first installment became exercisable on February 12, 2012.
  - (6) The option vests in monthly installments over four years. The first installment becomes exercisable on February 10, 2013.
  - (7) The restricted stock units will vest annually at 1/4 of the units vesting on January 10, 2014, January 10, 2015, January 10, 2016 and January 10, 2017, respectively.

## Edgar Filing: Gano Kyle - Form 3

(8) Each restricted stock unit represents a contingent right to receive one share of Neurocrine Biosciences, Inc. Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.